L L Zhang1, F F Cao, Y Wang, F L Meng, Y Zhang, D S Zhong, Q H Zhou. 1. Department of Oncology, Tianjin Medical University General Hospital, #154 Anshan Road, Heping District, Tianjin, 300052, China, zllcaroline@163.com.
Abstract
BACKGROUND: The application of newer signaling pathway-targeted agents has become an important addition to chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the efficacy and toxicities of PKC inhibitors combined with chemotherapy versus chemotherapy alone for patients with advanced NSCLC systematically. PATIENTS AND MATERIALS: Literature retrieval, trials selection and assessment, data collection, and statistic analysis were performed according to the Cochrane Handbook 5.1.0. The outcome measures were tumor response rate, disease control rate, progression-free survival (PFS), overall survival (OS), and adverse effects. RESULTS: Five randomized controlled trials, comprising totally 1,005 patients, were included in this study. Meta-analysis showed significantly decreased response rate (RR 0.79; 95 % CI 0.64-0.99) and disease control rate (RR 0.90; 95 % CI 0.82-0.99) in PKC inhibitors-chemotherapy groups versus chemotherapy groups. There was no significant difference between the two treatment groups regarding progression-free survival (PFS, HR 1.05; 95 % CI 0.91-1.22) and overall survival (OS, HR 1.00; 95 % CI 0.86-1.16). The risk of grade 3/4 neutropenia, leucopenia, and thrombosis/embolism increased significantly in PKC inhibitors combination groups as compared with chemotherapy alone groups. CONCLUSION: The use of PKC inhibitors in addition to chemotherapy was not a valid alternative for patients with advanced NSCLC.
BACKGROUND: The application of newer signaling pathway-targeted agents has become an important addition to chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). In this study, we evaluated the efficacy and toxicities of PKC inhibitors combined with chemotherapy versus chemotherapy alone for patients with advanced NSCLC systematically. PATIENTS AND MATERIALS: Literature retrieval, trials selection and assessment, data collection, and statistic analysis were performed according to the Cochrane Handbook 5.1.0. The outcome measures were tumor response rate, disease control rate, progression-free survival (PFS), overall survival (OS), and adverse effects. RESULTS: Five randomized controlled trials, comprising totally 1,005 patients, were included in this study. Meta-analysis showed significantly decreased response rate (RR 0.79; 95 % CI 0.64-0.99) and disease control rate (RR 0.90; 95 % CI 0.82-0.99) in PKC inhibitors-chemotherapy groups versus chemotherapy groups. There was no significant difference between the two treatment groups regarding progression-free survival (PFS, HR 1.05; 95 % CI 0.91-1.22) and overall survival (OS, HR 1.00; 95 % CI 0.86-1.16). The risk of grade 3/4 neutropenia, leucopenia, and thrombosis/embolism increased significantly in PKC inhibitors combination groups as compared with chemotherapy alone groups. CONCLUSION: The use of PKC inhibitors in addition to chemotherapy was not a valid alternative for patients with advanced NSCLC.
Authors: Johan Vansteenkiste; Jean-Luc Canon; Henrik Riska; Robert Pirker; Patrick Peterson; William John; Pekka Mali; Michael Lahn Journal: Invest New Drugs Date: 2005-06 Impact factor: 3.850
Authors: Erin M Casey; Wael Harb; Daniel Bradford; Jose Bufill; Sreenivasa Nattam; Jyoti Patel; William Fisher; Jane E Latz; Xiaochun Li; Jingwei Wu; Nasser Hanna Journal: J Thorac Oncol Date: 2010-11 Impact factor: 15.609
Authors: Jerome D Winegarden; Ann M Mauer; Thomas F Gajewski; Philip C Hoffman; Stuart Krauss; Charles M Rudin; Everett E Vokes Journal: Lung Cancer Date: 2003-02 Impact factor: 5.705
Authors: Verline Justilien; Michael P Walsh; Syed A Ali; E Aubrey Thompson; Nicole R Murray; Alan P Fields Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: Edward S Kim; Marcus Neubauer; Allen Cohn; Lee Schwartzberg; Lawrence Garbo; John Caton; Francisco Robert; Craig Reynolds; Terry Katz; Sreeni Chittoor; Lorinda Simms; Scott Saxman Journal: Lancet Oncol Date: 2013-11-12 Impact factor: 41.316
Authors: Corina E Antal; Andrew M Hudson; Emily Kang; Ciro Zanca; Christopher Wirth; Natalie L Stephenson; Eleanor W Trotter; Lisa L Gallegos; Crispin J Miller; Frank B Furnari; Tony Hunter; John Brognard; Alexandra C Newton Journal: Cell Date: 2015-01-22 Impact factor: 41.582